|
|
Volumn 23, Issue 6, 1995, Pages 989-991
|
|
Another negative clinical trial of a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections
|
|
Author keywords
bacterial infections; critical care; immunoglobulins; lipopolysaccharide; monoclonal antibodies; sepsis
|
|
Indexed keywords
BACTERIUM LIPOPOLYSACCHARIDE;
ENDOTOXIN;
IMMUNOGLOBULIN M;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY E5;
TUMOR NECROSIS FACTOR ALPHA;
UNCLASSIFIED DRUG;
CLINICAL FEATURE;
CLINICAL TRIAL;
DRUG EFFICACY;
EDITORIAL;
GRAM NEGATIVE SEPSIS;
HUMAN;
INTESTINE DIVERTICULOSIS;
MENINGOCOCCEMIA;
MORTALITY;
MULTICENTER STUDY;
NONHUMAN;
PATIENT SELECTION;
PERITONITIS;
PRIORITY JOURNAL;
SEPTIC SHOCK;
SURVIVAL RATE;
ANTIBODIES, MONOCLONAL;
GRAM-NEGATIVE BACTERIAL INFECTIONS;
HUMAN;
IMMUNOGLOBULIN M;
IMMUNOGLOBULINS;
RANDOMIZED CONTROLLED TRIALS;
SEPSIS;
|
|
EID: 0029034914
PISSN: 00903493
EISSN: None
Source Type: Journal
DOI: 10.1097/00003246-199506000-00001 Document Type: Editorial |
|
Times cited : (50)
|
|
References (0)
|
